What to do if a woman has a uterine tumor

Uterine tumors may represent uterine fibroids. Of course, patients need to go to the hospital for examination and diagnosis before they can receive the correct treatment. So what should women do if they develop uterine tumors? First of all, they should treat the disease, pay attention to rest after treatment, and then carry out disease care to prevent the disease from recurring. Although uterine fibroids do not affect life safety, they are harmful to uterine health, so treatment is very important. The following will explain to you the treatment methods of the disease.

Traditional Chinese Medicine Treatment

Traditional Chinese medicine believes that uterine fibroids are caused by organ dysfunction, qi stagnation and blood stasis. Therefore, traditional Chinese medicine treats uterine fibroids mainly by promoting blood circulation and removing blood stasis, eliminating blood stasis and dispersing nodules, clearing away heat and detoxifying, soothing the liver and regulating qi, and removing blood stasis and relieving pain. Traditional Chinese medicine treatment of uterine fibroids can improve the blood circulation of the hyperplastic endometrium, gradually eliminate the simple hypertrophy of the muscle layer, and soften the hyperplastic connective tissue, thereby playing a therapeutic role in regulating menstruation, stopping bleeding, eliminating pain, and restoring ovarian function. It can effectively control the growth of uterine fibroids, gradually soften the tumor, and finally dissipate. Yushantang Qingji Patch has a very good effect on the treatment of uterine fibroids and has successfully cured many female friends. Qingji Patch uses black plaster as an internal external medium and adopts the method of internal disease external treatment to achieve the purpose of curing uterine fibroids. No surgery or medication required, just a simple patch can cure uterine fibroids.

Drug treatment

(I) Indications for drug treatment

1. Young people who want to preserve their fertility. For women of childbearing age who suffer from infertility or miscarriage due to fibroids, drug treatment can shrink the fibroids and promote conception and fetal survival.

2. For premenopausal women, the fibroids are not very large and the symptoms are mild. After taking the medicine, the uterus will shrink and menopause will occur, and the fibroids will shrink accordingly, thus avoiding surgery.

3. Those who have surgical indications but currently have contraindications and need to be treated before surgery.

4. Patients with concurrent medical or surgical diseases who are unable to undergo surgery or are unwilling to undergo surgery.

5. Before choosing drug treatment, a diagnostic curettage and endometrial biopsy should be performed to rule out malignant changes, especially for those with menstrual disorders or increased menstrual flow. Curettage has both diagnostic and hemostatic functions.

The basis of drug treatment is that uterine fibroids are sex hormone-dependent tumors, so drugs that antagonize sex hormones are used for treatment. Newly used drugs are those that temporarily suppress the ovaries.

(II) Drug types and usage

1. LHRH agonist (LHRH-A): GnRHa is a new type of anti-gynecological disease drug in recent years. After continuous use of large amounts of LHRH, the pituitary cell receptors are filled with hormones and are unable to synthesize and release FSH and LH. In addition, LHRH has extrapituitary effects. Large doses of LHRH increase the number of LHRH receptors on the ovaries, reducing the ovaries' ability to produce estrogen and progesterone. Because the drug significantly inhibits FSH and reduces ovarian hormone secretion, its effect is similar to "medical oophorectomy", causing the fibroids to shrink. LHRH and LHRH-A are isoforms with the same function, but the latter is dozens of times more active than the former.

Usage: LHRH-A is usually injected intramuscularly, but can also be implanted subcutaneously or sprayed into the nose. Inject 100-200 μg intramuscularly from the first day of menstruation for 3-4 months. Its effects depend on the dose applied, route of administration and the timing of the menstrual cycle. After taking the medicine, the fibroids shrank by an average of 40 to 80%, symptoms were relieved, and anemia was corrected. The decrease in serum E2 is consistent with the reduction of fibroids. There was no significant change in FSH and LH. Soon after stopping the drug, the fibroids grew again, indicating that the effect of LHRH-A is temporary and reversible. If used in perimenopause, natural menopause can be achieved within a limited time. For example, if it is used for fertility preservation, when the fibroids shrink and local blood flow decreases, bleeding during surgery and the scope of surgery can be reduced; or if the fibroids originally affected the fallopian tube opening, after treatment the fibroids will shrink, making the blocked fallopian tubes unobstructed, thereby increasing the pregnancy rate. In order to reduce the regrowth of fibroids after discontinuation of medication, 200-500 mg of medroxyprogesterone acetate can be used sequentially when using LHRH-A to maintain its therapeutic effect.

Side effects are hot flashes, sweating, vaginal dryness, or bleeding disorders. Osteoporosis may occur due to low estrogen effects.

2. Danazol: has a weak androgenic effect. Danazol inhibits the function of the hypothalamus and pituitary gland, causing a decrease in FSH and LH levels, thereby inhibiting the production of ovarian steroids. It can also directly inhibit the enzymes that produce ovarian steroids. This causes the estrogen level in the body to drop, inhibiting uterine growth, causing endometrial atrophy and amenorrhea. At the same time, the fibroids also shrink and become smaller. However, for young women, menstruation can resume 6 weeks after stopping the medication. Therefore, repeated application is required.

Surgery

For patients with fibroids, the age for hysterectomy was previously set at over 45 years old. It now seems that we need to proceed from reality, especially based on the progress of gynecological endocrinology. The age limit for ovarian preservation is generally 50 years old (the average age of menopause is 49.5 years old), that is, those under 50 years old who can preserve their ovaries should do so. Or the normal ovaries of those who have not reached menopause after the age of 50 should also be preserved, regardless of age. Because, normally after menopause, the ovaries still have certain endocrine functions and continue to work for 5 to 10 years. Preserving the ovaries helps stabilize the autonomic nervous system, regulate metabolism, and facilitate the transition to old age. The uterus also has its endocrine function. It is the target organ of the ovaries and should not be removed casually. The age for hysterectomy is usually set at over 45 years old. Those under 45 years old, especially those under 40 years old, are suitable for myomectomy. For those who undergo attachment preservation, if both sides can be preserved, it is better to preserve both sides rather than just one side. The incidence of ovarian cancer in women who retain their ovaries is 0.15%, which is no higher than that in women who do not have their uterus removed.

What should women do if they develop uterine tumors? It is most important for patients to receive medical treatment immediately. After the disease is diagnosed, patients should maintain an open-minded character. There are many types of treatments for benign tumors, and the size of the tumor must also be considered. After the doctor develops a treatment plan for the patient, we must take the medicine according to the doctor's orders. If the fibroids meet the surgical standards, we must be admitted to the hospital for treatment immediately. After treatment, the fibroids will disappear, but we must also prevent the recurrence of the disease.